Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.
Stocks · News reference
Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa ResultsRamat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF),
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Can-Fite BioPharma shares are trading lower after the company said blinded overall survival in its Phase III Namodenoson study for advanced HCC appears longer than expected under the trial design assumptions.
Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
Can-Fite Plans To Advance Interim Analysis Of Phase III Namodenoson Study In Advanced Hepatocellular Carcinoma